Treatment of painful radiculopathies with capsaicin 8% cutaneous patch

References

• Romano CL, Romano D, Lacerenza M. Antineuropathic and antinociceptive drugs combination in patients with chronic low back pain: a systematic review. Pain Res Treat 2012, published online, doi: 10.1155/2012/154781
   Google Scholar
• Förster M, Mahn F, Baron R. Die neuropathische Komponente beim chronischenx Rückenschmerz. Nervenheilkunde 2012;31:147-53
   Google Scholar
• Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 2004;140:441-51
   PubMed Web of Science ®Google Scholar
• Schmidt CO, Schweikert B, Wenig CM, et al. Modelling the prevalence and cost of back pain with neuropathic components in the general population. Eur J Pain 2009;13:1030-5
   PubMed Web of Science ®Google Scholar
• Johnson JA, Pickard AS. Comparison of the EQ-5D and SF-12 health surveys in a general population survey in Alberta, Canada. Med Care 2000;38:115-21
   PubMed Web of Science ®Google Scholar
• Luo N, Johnson JA, Shaw JW, et al. Self-reported health status of the general adult U.S. population as assessed by the EQ-5D and Health Utilities Index. Med Care 2005;43:1078-86
   PubMed Web of Science ®Google Scholar
• Doth AH, Hansson PT, Jensen MP, et al. The burden of neuropathic pain: a systematic review and meta-analysis of health utilities. Pain 2010;149:338-44
   PubMed Web of Science ®Google Scholar
• Montazeri A, Mousavi SJ. Quality of Life and Low Back Pain. New York: Springer, 2010. Available at: http://link.springer.com/referenceworkentry/10.1007/978-0-387-78665-0_232/fulltext.html. Last accessed 2016 Dec 14
   Google Scholar
• Kuijper B, Tans JT, Schimsheimer RJ, et al. Degenerative cervical radiculopathy: diagnosis and conservative treatment. A review. Eur J Neurol 2009;16:15-20
   PubMed Web of Science ®Google Scholar
• Thoomes EJ, Scholten-Peeters GGM, de Boer AJ, et al. Lack of uniform diagnostic criteria for cervical radiculopathy in conservative intervention studies: a systematic review. Eur Spine J 2012;21:1459
   PubMed Web of Science ®Google Scholar
• Diener H, Weimar C, Berlit P et al., eds. Leitlinien für Diagnostik und Therapie in der Neurologie. 74 Zervikale Radikulopathie. Thieme 5th edn. 2012:902-7
   Google Scholar
• Diener H, Weimar C, Berlit P et al., eds. Leitlinien für Diagnostik und Therapie in der Neurologie. 75 Lumbale Radikulopathie. Thieme 5th edn. 2012:908-20
   Google Scholar
• Bono CM, Ghiselli G, Gilbert TJ, et al. An evidence-based clinical guideline for the diagnosis and treatment of cervical radiculopathy from degenerative disorders. Spine J 2011;11:64-72
   PubMed Web of Science ®Google Scholar
• Lee J, Gupta S, Price C, et al. Low back and radicular pain: a pathway for care developed by the British Pain Society. Br J Anaesth 2013;111:112-20
   PubMed Web of Science ®Google Scholar
• Caridi JM, Pumberger M, Hughes AP. Cervical radiculopathy: a review. HSS J 2011;7:265-72
   PubMedGoogle Scholar
• Baron R, Binder A, Attal N, et al. Neuropathic low back pain in clinical practice. Eur J Pain 2016;20:861-73
   PubMed Web of Science ®Google Scholar
• Johnston HM. The cutaneous branches of the posterior primary divisions of the spinal nerves, and their distribution in the skin. J Anat Physiol 1908;43(Pt 1):80-92.5
   PubMedGoogle Scholar
• Rao R. Neck pain, cervical radiculopathy, and cervical myelopathy: pathophysiology, natural history, and clinical evaluation. Instr Course Lect 2003;52:479-88
   PubMedGoogle Scholar
• Qutenza 179mg cutaneous patch – Summary of Product Characteristics (SPC) – (eMC). Astellas Pharma Europe BV, 2015. Available at: https://www.medicines.org.uk/emc/medicine/23156 [Last accessed 31 March 2017]
   Google Scholar
• Bogduk N. On the definitions and physiology of back pain, referred pain, and radicular pain. Pain 2009;147:17-19
   PubMed Web of Science ®Google Scholar
• Hildebrandt J, Schöps P. Schmerzen am Bewegungsapparat/Rückenschmerz. In: Zenz M, Jurna I, Ahrens S, Zenz J, eds. Lehrbuch der Schmerztherapie Grundlagen, Theorie und Praxis für Aus- und Weiterbildung. Stuttgart: Wiss. Verl.-Ges., 2001:577-92
   Google Scholar
• Ladeira CE. Evidence based practice guidelines for management of low back pain: physical therapy implications. Rev Bras Fisioter 2011;15:190-9
   PubMedGoogle Scholar
• Visco CJ, Cheng DS, Kennedy DJ. Pharmaceutical therapy for radiculopathy. Phys Med Rehabil Clin N Am 2011;22:127-37
   PubMed Web of Science ®Google Scholar
• NICE. Low back pain and sciatica in over 16s: assessment and management. NICE guideline [NG59], November 2016. Available at: https://www.nice.org.uk/guidance/ng59/resources/low-back-pain-and-sciatica-in-over-16s-assessment-and-management-1837521693637. Last accessed 2016 Dec 14
   Google Scholar
• Khoromi S, Cui L, Nackers L, Max MB. Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain 2007;130:66-75
   PubMed Web of Science ®Google Scholar
• McCleane GJ. Does gabapentin have an analgesic effect on background, movement and referred pain? A randomised, double-blind, placebo controlled study. Pain Clinic 2001;13:103-7
   Web of Science ®Google Scholar
• Baron R, Freynhagen R, Tolle TR, et al. The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. Pain 2010;150:420-7
   PubMed Web of Science ®Google Scholar
• Attal N. Neuropathic pain: mechanisms, therapeutic approach, and interpretation of clinical trials. Continuum Lifelong Learning Neurol 2012;18:161-75
   Google Scholar
• Caterina MJ, Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Annu Rev Neurosci 2001;24:487-517
   PubMed Web of Science ®Google Scholar
• Cortright DN, Szallasi A. Biochemical pharmacology of the vanilloid receptor TRPV1. An update. Eur J Biochem 2004;271:1814-19
   PubMedGoogle Scholar
• Caterina MJ. Vanilloid receptors take a TRP beyond the sensory afferent. Pain 2003;105:5-9
   PubMed Web of Science ®Google Scholar
• Alawi K, Keeble J. The paradoxical role of the transient receptor potential vanilloid 1 receptor in inflammation. Pharmacol Ther 2010;125:181-95
   PubMed Web of Science ®Google Scholar
• Kennedy WR, Vanhove GF, Lu SP, et al. A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers. J Pain 2010;11:579-87
   PubMed Web of Science ®Google Scholar
• Malmberg AB, Mizisin AP, Calcutt NA, et al. Reduced heat sensitivity and epidermal nerve fiber immunostaining following single applications of a high-concentration capsaicin patch. Pain 2004;111:360-7
   PubMed Web of Science ®Google Scholar
• Nolano M, Simone DA, Wendelschafer-Crabb G, et al. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain 1999;81:135-45
   PubMed Web of Science ®Google Scholar
• Backonja M, Wallace MS, Blonsky ER, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol 2008;7:1106-12
   PubMed Web of Science ®Google Scholar
• Irving GA, Backonja MM, Dunteman E, et al. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med 2011;12:99-109
   PubMed Web of Science ®Google Scholar
• Simpson DM, Brown S, Tobias J. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 2008;70:2305-13
   PubMed Web of Science ®Google Scholar
• Clifford DB, Simpson DM, Brown S, et al. A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. J Acquir Immune Defic Syndr 2012;59:126-33
   PubMed Web of Science ®Google Scholar
• Simpson DM, Robinson-Papp J, Van J, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study. J Pain 2017;18:42-53
   PubMed Web of Science ®Google Scholar
• Vinik AI, Perrot P, Vinik EJ, et al. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study. BMC Neurol 2016;16:251
   PubMed Web of Science ®Google Scholar
• Gálvez R, Navez M-L, Moyle G, et al. Capsaicin 8% patch repeat treatment in non-diabetic peripheral neuropathic pain: a 52-week, open-label, single-arm, safety study. Clin J Pain 2016: published online December 2016, doi: 10.1097/AJP.0000000000000473
   PubMed Web of Science ®Google Scholar
• Burness CB, McCormack PL. Capsaicin 8% patch: a review in peripheral neuropathic pain. Drugs 2016;76:123-34
   PubMed Web of Science ®Google Scholar
• Haanpää M, Cruccu G, Nurmikko TJ, et al. Capsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain. Eur J Pain 2016;20:316-28
   PubMed Web of Science ®Google Scholar
• Kern KU, Baust H, Hofmann W, et al. Capsaicin 8% cutaneous patches for phantom limb pain. Results from everyday practice (non-interventional study) [Das 8%ige Capsaicin-Pflaster bei Phantomschmerz. Ergebnisse aus dem Praxisalltag (nichtinterventionelle Studie)]. Schmerz 2014;28:374-83
   PubMed Web of Science ®Google Scholar
• Husstedt IW, Heskamp M-LS, Maihöfner CG. Treatment of chemotherapy-induced polyneuropathies: effectiveness and safety of the capsaicin 8% cutaneous patch. Poster abstract 3082, poster PF-434. WCP (IASP), Buenos Aires, 6–11 October 2014
   Google Scholar
• Maihöfner CG, Kötteritz P, Heskamp M-LS. CRPS: Effektivität und Sicherheit von Capsaicin 8% kutanes Pflaster. Subgruppenanalyse der QUEPP-Studie. Congress of Deutsche Schmerzgesellschaft. Poster P04.6. Hamburg, Germany, 23–26 October 2013
   Google Scholar
• Bischoff JM, Ringsted TK, Petersen M, et al. A capsaicin (8%) patch in the treatment of severe persistent inguinal postherniorrhaphy pain: a randomized, double-blind, placebo-controlled trial. PloS One 2014;9:6109144
   Web of Science ®Google Scholar
• Prosenz J, Neuwersch SM, Likar R, et al. The effect of a single treatment with capsaicin 8% patch in neuropathic chronic low back pain – a pilot study. Poster abstract 234, Poster PO19, 9th congress of the European Pain Federation (EFIC), Vienna, Austria, 2–5 September 2015
   Google Scholar
• Derry S, Rice ASC, Cole P, et al. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2017;1:CD007393
   PubMed Web of Science ®Google Scholar
• Acorda Therapeutics Inc. Qutenza (capsaicin) 8% patch: US prescribing information. 2016. Available at: http://www.qutenza.com [Last accessed 31 March 2017]
   Google Scholar
• Maihöfner C, Heskamp ML. Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study. Curr Med Res Opin 2013;29:673-83
   PubMed Web of Science ®Google Scholar
• Maihöfner CG, Heskamp ML. Treatment of peripheral neuropathic pain by topical capsaicin: impact of pre-existing pain in the QUEPP-study. Eur J Pain 2014;18:671-9
   PubMed Web of Science ®Google Scholar
• Höper J, Helfert S, Heskamp ML, et al. High concentration capsaicin for treatment of peripheral neuropathic pain: effect on somatosensory symptoms and identification of treatment responders. Curr Med Res Opin 2014;30:565-74
   PubMed Web of Science ®Google Scholar
• Weltärztebund (WMA). Deklaration Von Helsinki, Ethische Grundsätze für die medizinische Forschung am Menschen 2008; DoH_SEOUL2008‐DE_Final_100211. Available at: http://www.aerzteblatt.de/down.asp?typ=PDF&id = 5324 [Last accessed 1 April 2016]
   Google Scholar
• International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH): ICH Harmonised Tripartite Guideline, Guideline for Good Clinical Practice E6(R1). 1996; http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/good-clinical-practice.html. Last accessed 2016 Dec 14
   Google Scholar
• Freynhagen R, Baron R, Gockel U, et al. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22:1911-20
   PubMed Web of Science ®Google Scholar
• Hüllemann P, Keller T, Kabelitz M, et al. Pain drawings improve subgrouping of low back pain patients. Pain Pract 2017;17:293-304
   PubMed Web of Science ®Google Scholar
• Hildebrandt J, Pfingsten M. Rückenschmerz und Lendenwirbelsäule, Interdisziplinäres Praxisbuch; entsprechend den Nationalen Versorgungsleitlinien, 2nd edn. s.l. Urban Fischer Verlag – Nachschlagewerke, 2011. Available at: http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN = 808078. Last accessed 2016 Dec 14
   Google Scholar
• Saldana MT, Navarro A, Perez C, et al. Patient-reported-outcomes in subjects with painful lumbar or cervical radiculopathy treated with pregabalin: evidence from medical practice in primary care settings. Rheumatol Int 2010;30:1005-15
   PubMed Web of Science ®Google Scholar
• Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth 2011;107:490-502
   PubMed Web of Science ®Google Scholar
• Stanos SP, Galluzzi KE. Topical therapies in the management of chronic pain. Postgrad Med 2013;125:25-33
   PubMedGoogle Scholar
• Maihöfner C (Hrsg.) Moderne Praxis der analgetischen Lokaltherapie (UNI-MED Science), 1st edn. 2016, Bremen, Germany: UNI-MED Verlag Aktiengesellschaft
   Google Scholar
• Mahn F, Hullemann P, Gockel U, et al. Sensory symptom profiles and co-morbidities in painful radiculopathy. PLoS One 2011;6:e18018
   PubMed Web of Science ®Google Scholar
• Wagner T, Poole C, Roth-Daniek A. The capsaicin 8% patch for neuropathic pain in clinical practice: a retrospective analysis. Pain Med 2013;14:1202-11
   PubMed Web of Science ®Google Scholar
• Vocelka M, Dolezal T, Klimes J, et al. Effectiveness of 8% capsaicin patch in real clinical practice – 12-month result. Bolest Rocnik 2013;16:34-8
   Google Scholar